|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's range||5.94 - 6.13|
|52-week range||2.25 - 7.35|
|Beta (5Y monthly)||-0.75|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
If you want to know who really controls BELLUS Health Inc. ( TSE:BLU ), then you'll have to look at the makeup of its...